Which indication is appropriate for MAA treatment?

The appropriate indication for MAA (Macroaggregated Albumin) treatment is non-resectable primary liver cancer. This treatment is typically associated with radioembolization procedures that target liver tumors. In cases of non-resectable primary liver cancer, MAA is used to deliver targeted radiation therapy specifically to the tumor. This method helps control tumor growth and can improve the patient's quality of life while potentially extending survival.

The strategy behind using MAA in this context stems from its ability to selectively lodge in the blood vessels feeding the tumors, delivering localized radiation without significant harm to surrounding healthy liver tissue. This is particularly advantageous for patients who are not candidates for surgical resection due to the extent or location of the tumors.

In contrast, resectable liver cancer would aim for surgical intervention rather than a palliative approach like MAA treatment. Severe liver inflammation and acute liver failure are conditions where MAA treatment would not be indicated, as they do not involve a primary tumor situation suitable for this type of targeted therapy. Instead, these conditions may require different types of medical management or therapeutic strategies focused on managing liver function and inflammation rather than targeting tumors.